Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On September 9, 2021, the Board of Directors (the "Board") of DaVita Inc. (the
"Company") adopted resolutions expanding the size of the Board from eight to
nine members, and appointed Gregory J. Moore, M.D., Ph.D. as a member of the
Board, to fill the newly created vacancy on the Board, in each case effective as
of September 9, 2021. The Board also appointed Dr. Moore to serve as a member of
the Nominating and Governance Committee and Compliance and Quality Committee of
the Board effective as of September 9, 2021.
Dr. Moore will receive the standard compensation and indemnification applicable
to all other non-employee directors. We have described our Non-Employee Director
Compensation Policy in our Proxy Statement on Schedule 14A filed with the U.S.
Securities and Exchange Commission (the "SEC") on April 23, 2021. The form of
indemnification agreement we entered into with Dr. Moore is an exhibit to our
Current Report on Form 8-K filed with the SEC on December 20, 2006.
No arrangement or understanding exists between Dr. Moore and any other person or
persons pursuant to which he was selected as a director. The Company has not
been a participant in any transaction since the beginning of its last fiscal
year, and is not a participant in any currently proposed transaction, in which
Dr. Moore, or any member of his immediate family, had or will have a direct or
indirect material interest.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses